Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 2, 1996, Pages 213-216

  Bocola, V ^a   Fabbrini, G ^b   Sollecito, A ^a   Paladini, C ^a   Martucci, N ^c  

^a Casa di Cura Villa Pini d'Abruzzo Policlinico Abano Terme   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Istituto Neurotraumatologico Italiano   (Italy)

Author keywords

Magnetic resonance imaging; Neuroleptic drugs; Parkinsonism

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; STRIATE CORTEX; SYMPTOM;

EID: 0030038799     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.2.213     Document Type: Article

References (30)

1. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinico-pathological study of two cases. Arch Neurol 1982; 39:644-6.
2. Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 1991;14:273-8.
3. Ayd F. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-60.
4. Klawans HL, Bergen D, Bruyn GW. Prolonged drug-induced parkinsonism. Confin Neurol 1973;35:368-77.
5. Crane G. Persistence of neurological symptoms due to neuroleptic drugs. Am J Psychiatry 1971;127:143-6.
6. Aronson AT. Persistent drug induced parkinsonism. Biol Psychiatry 1985;20:795-8.
7. 18F-dopa PET study. Neurology 1993; 43:552-6.
8. Myrianthopoulos NC, Waldrop FN, Vincent BL. A repeat study of hereditary predisposition in drug-induced parkinsonism. In: Barbeau A, Brunette JR, eds. Progress in neurogenetics. Amsterdam: Excerpta Medica International Congress Series 1969;175:486-91.
9. Nielsen EB, Lyon M. Evidence for cell loss in corpus striarum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 1978;58:85-9.
10. Goetz CG. Drug-induced parkinsonism and idiopathic Parkinson's disease. Arch Neurol 1983;40:325-6.
11. Figiel GS, Krishnan RR, Doraiswamy M, Nemeroff CB. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism. J Geriatr Psychiatry Neurol 1991;4:86-9.
12. Parkinson study group. DATATOP: a multicenter controlled trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.
13. Stephen PJ, Williamson J. Drug induced parkinsonism in the elderly. Lancet 1984;10:1082-3.
14. Hausner RS. Neuroleptic induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. J Clin Psychiatry 1983;44:13-6.
15. Sehti KD, Zamrini EY. Asymmetry in clinical features of drug induced parkinsonism. J Neuropsychiatry Clin Neurosci 1990;2:64-6.
16. Grafton ST, Sumi SM, Stimac GK, Alvord EC Jr, Shaw CM, Nochlin D. Comparison of postmortem magnetic resonance imaging and neuropathologic findings in the cerebral white matter. Arch Neurol 1991;48:293-8.
17. Kirkpatrick JB, Hayman LA. White matter lesions in MR imaging of clinically healthy brains of elderly subjects: possible pathological basis. Radiology 1988;169:101-4.
18. Thajeb P. Gait disorders of multi-infarct dementia. CT and clinical correlation. Acta Neurol Scand 1993;87:239-42.
19. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987;2:1-8.
20. Halliwell DS. Oxygen radicals as key mediators in neurological diseases: fact or fiction? Ann Neurol 1992;32: S10-5.
21. Floyd IA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 1992;32: S22-7.
22. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer P. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986;159: 483-8.
23. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron and ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75.
24. Ben-Shachar D, Youdim MBH. Neuroleptic induced dopamine receptor supersensitivity and tardive dyskinesia may involve altered brain iron metabolism. Br J Pharmacol 1987;90:95.
25. Rajan KS, Manian JM, Davis JM, Skripkus A. Studies on the metal chelation of chlorpromazine and its hydroxylated metabolites. In: Forrest IS, Carra CJ, Usdin E, eds. The phenothiazines and structurally related drugs. New York: Raven Press 1974:571-91.
26. Casanova MF, Comparini SO, Kim RW, Kleinman JE. Staining intensity of brain iron in patients with schizophrenia: a post-mortem study. J Neuropsychiatry Clin Neurosci 1992;4:36-11.
27. Casanova MF, Waldman IN, Kelinman JE. A post-mortem quantitative study of iron in the globus pallidus of schizophrenic patients. Biol Psychiatry 1990;27:143-9.
28. Campbell WG, Raskind MA, Gordon T, Shaw CM. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry 1985;142:364-5.
29. Christensen E, Moller JE. Neuropathological investigation of 28 brains from patients with dyskinesias. Acta Psychiatr Scand 1980;46:14-23.
30. Heinz R, Rayasam K, Krishnan RR, Wingfield M, Irigaray P, Ellinwood EH. MRI scans in patients with tardive dyskinesias. Biol Psychiatry 1988;24:852-60.